MedTrace Logo

This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants

NCT06736912 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-12-17

No results posted yet for this study

Summary

This study aims to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties and food effect of IN-114199 in healthy participants

Conditions

  • Chronic Idiopathic Constipation

Interventions

DRUG

IN-114199 2.5mg or placebo

IN-114199 2.5mg or placebo (1 Tablet, QD)

DRUG

IN-114199 10mg or placebo

IN-114199 10mg or placebo (1 Tablet, QD)

DRUG

IN-114199 20mg or placebo

IN-114199 10mg or placebo (2 Tablets, QD)

DRUG

IN-114199 40mg or placebo

IN-114199 10mg or placebo (4 Tablets, QD)

DRUG

IN-114199 5mg or placebo

IN-114199 2.5mg or placebo (2 Tablets, QD)

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
63 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2025-08-30
Completion
2025-11-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06736912 on ClinicalTrials.gov